Get the Stockscreener App
92.77
0.19%
0.18
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $92.77, with a volume of 5.55M.
It is up +0.19% in the last 24 hours and up +0.28% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$92.59
Open:
$93.03
24h Volume:
5.55M
Relative Volume:
0.88
Market Cap:
$287.64B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
30.81
EPS:
3.0115
Net Cash Flow:
$9.87B
1W Performance:
-0.19%
1M Performance:
+0.28%
6M Performance:
+21.13%
1Y Performance:
+30.22%
1-Day Range:
$92.46
$93.51
1-Week Range:
$92.46
$96.18
52-Week Range:
$61.24
$96.51
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
92.77 | 287.08B | 58.07B | 9.40B | 9.87B | 3.0115 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Is AstraZeneca (LSE:AZN) Offering Value After Steady Gains And Strong Pipeline Developments - Yahoo Finance UK
Astrazeneca doubles down on China with $15B+ investments - BioWorld MedTech
AstraZeneca (AZN) Stock: Surges as $1.2B CSPC Obesity Drug Deal Unlocks Global Expansion - parameter.io
AstraZeneca Beats FMLA Suit After Ex-Worker Went Silent - Law360
Precidian Funds, Announces the Liquidation of AstraZeneca PLC ADRhedged - morningsun.net
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC - BioPharma Dive
AstraZeneca makes $18.5bn bet on CSPC’s weight loss drugs - BioXconomy
AstraZeneca announces $1.2 billion obesity and diabetes deal with CSPC By Investing.com - Investing.com South Africa
AstraZeneca PLCAstraZeneca agrees obesity and T2D deal with CSPC - Research Tree
AstraZeneca obesity tie-up with CSPC seen as shrewd move - Proactive financial news
AstraZeneca Expands Weight Loss Push With Eight-Program China Collaboration - Benzinga
AstraZeneca (AZN) Expands Weight Management Initiatives with CSP - GuruFocus
AstraZeneca signs $4.7bn weight loss drug deal with CSPC - Pharmaceutical Technology
AstraZeneca announces $1.2 billion obesity and diabetes deal with CSPC - Investing.com
AstraZeneca Seals China Obesity Drug Deal For Up To $18.5B - Law360
AstraZeneca (AZN) commits $1.2B upfront in CSPC obesity and diabetes partnership - Stock Titan
CSPC Pharmaceutical Group Limited Enters into Strategic Collaboration and License Agreement with AstraZeneca for the Development of Innovative Long-Acting Peptide Medicines - marketscreener.com
AstraZeneca Bets $18.5bn On CSPC’s Sustained-Release And AI Peptide Platforms In Weight Management - Citeline News & Insights
AstraZeneca Strikes Obesity Multibillion-Dollar Deal With China's CSPC Pharmaceuticals -- Update - marketscreener.com
AstraZeneca teams up with Chinese firm in $18.5bn deal for weight loss drugs - business-live.co.uk
AstraZeneca to Pay $1.2 Billion Upfront to CSPC Pharmaceuticals to Expand Weight Management Portfolio - marketscreener.com
CSPC Pharma Shares Drop on Possible Profit-Taking After AstraZeneca Deal - marketscreener.com
AstraZeneca strikes obesity deal with China's CSPC Pharmaceuticals - marketscreener.com
Trending tickers: Apple, Microsoft, Sandisk, Caterpillar and AstraZeneca - Yahoo Finance UK
Astrazeneca Secures Tie-up With Chinese Firm For Weight Loss Drugs - bernama
AstraZeneca (AZN) Secures $18.5B Deal for Obesity Drug Developme - GuruFocus
AstraZeneca Strengthens Its Weight Management Portfolio Through New Strategic Collaboration Agreement with CSPC Pharmaceuticals - marketscreener.com
Astra Signs Obesity Deal in China Worth Up to $18.5 Billion - Bloomberg.com
AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals - Sharecast.com
AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical (AZN:NASDAQ) - Seeking Alpha
AstraZeneca secures tie-up with Chinese firm for weight loss drugs - Yahoo Finance UK
AstraZeneca Secures Access to CSPC Pharmaceuticals' Weight Management Portfolio - marketscreener.com
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC - marketscreener.com
AstraZeneca strikes $1.2bn obesity drug deal with China's CSPC - Proactive financial news
REGAstraZeneca PLCAstraZeneca agrees obesity and T2D deal with CSPC - TradingView
AstraZeneca to pay CSPC Pharma up to $18.5 billion for obesity drugs By Investing.com - Investing.com UK
AstraZeneca (AZN) Partners with CSPC for Obesity Drug Developmen - GuruFocus
China’s CSPC Pharma inks $1.2 bln peptide deal with AstraZeneca By Investing.com - Investing.com Australia
China’s CSPC Pharma inks $1.2 bln peptide deal with AstraZeneca - Investing.com
CSPC PHARMA Partners with AstraZeneca to Develop Innovative Long-Acting Peptide Medicines w/ Upfront Payment of $9.3B+, Yet Shr Price Plunges 10% - AASTOCKS.com
Astra Touts $15 Billion China Investment During Starmer Trip - Bloomberg.com
AstraZeneca strikes deal for up to $18.5 billion to license weight-loss drugs from China's CSPC - Reuters
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy - marketscreener.com
CSPC Pharmaceutical Group enters strategic collaboration and license agreement with AstraZeneca - marketscreener.com
What’s the outlook for AstraZeneca PLC Depositary Receipt’s sectorJuly 2025 Gainers & Community Verified Trade Signals - mfd.ru
Oakmark Global Strategy Outperforms, Adds AstraZeneca (AZN) and Gartner (IT) - GuruFocus
Europe bulletin: UK’s ‘long-term’ China play, war tech problems, AstraZeneca’s $15B bet By Invezz - Investing.com UK
AstraZeneca Bets Big On China With Massive $15 Billion Investment - Benzinga
AstraZeneca strengthens China ties with planned $15B investment - BioPharma Dive
AstraZeneca to invest $15 billion in China for R&D and manufacturing by 2030 By Investing.com - Investing.com Nigeria
AstraZeneca plans $15bn investment in China by 2030 to expand R&D - Investment Monitor
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):